This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
During its quarterly earnings presentation, Vertex said that it expects to begin...
The German drugmaker confirmed acquisition talks, but cautioned a deal may not m...
Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its st...
Herbal medicinal product: Boldi foliumArray, C: ongoing call for scientific data
Early diagnosis and treatment of ADHD could help prevent young people from picki...
Human medicines European public assessment report (EPAR): CoAprovel, irbesartan,...
Human medicines European public assessment report (EPAR): Karvezide, irbesartan,...
Voyager Therapeutics no longer expects to take its amyotrophic lateral sclerosis...
Human medicines European public assessment report (EPAR): Repaglinide Teva, repa...
Merck KGaA is in advanced talks to acquire cancer and rare disease specialist Sp...
Webinar on PMS Project Made Easy: Summary of activities and Practical Tips for S...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
Human medicines European public assessment report (EPAR): Aprovel, irbesartan, D...
Executive Steering Group on Shortages and Safety of Medicinal Products
In the latest edition of STAT's Health Tech newsletter: Biotech companies and hy...
Ebola cases in Uganda have risen to nine, while 265 other people were being moni...
Human medicines European public assessment report (EPAR): Ultibro Breezhaler, in...
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and ret...
Human medicines European public assessment report (EPAR): Armisarte (previously ...
Human medicines European public assessment report (EPAR): Pluvicto, lutetium (17...
New Hampshire’s Bio X Cell, which has made a name for itself over the past quart...
Older millennials, take note: Bayer is worried about your heart health. The drug...